Clinical trials: Cachexia-Anorexia Syndrome, open to volunteers
Cachexia-Anorexia Syndrome, Cachexia; Cancer
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.
- Trial name
- NCT07890324
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome
Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer
Cancer anorexia-cachexia syndrome is a common and severe complication in patients with advanced cancer, with a particularly high prevalence in pancreatic cancer.
- Trial name
- NCT07408505
- Testing
- Nano-crystalline megestrol acetate, First-line Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shandong Cancer Hospital and Institute
Cancer, Cachexia
Neurobehavioural and Cognitive Changes in Cancer Cachexia (CANCOG)
The goal of this observational study is to to look for changes within the brain, and changes in body-to-brain signals in people with cancer and people who do not have cancer. The main questions it aims to answer are: 1.
- Conditions
- Cancer, Cachexia, Cachexia-Anorexia Syndrome, Appetite Loss
- Trial name
- CANCOG (NCT06112964)
- Testing
- MRI/ Functional MRI, Self-reported questionnaires, Computer based tasks
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Cachexia-Anorexia Syndrome
Feasibility Study for Repurposing RET Inhibitors
The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
- Trial name
- FEATHER (NCT07146893)
- Testing
- Selpercatinib, Strength Assessment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Oklahoma
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Cancer - Associated Anorexia - Cachexia Syndrome
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
Patients with extensive-stage small cell lung cancer are a high-risk group for cancer cachexia and anorexia. Meanwhile, the adverse reactions of chemotherapy and immunotherapy potentially exacerbate the occurrence and development…
- Trial name
- NCT06909383
- Testing
- Nanocrystalline megestrol acetate
- Volunteers
- 41 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Lung Cancer, Cachexia-Anorexia Syndrome
Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer
Patients with advanced lung cancer are a high-risk population for cancer-related anorexia-cachexia syndrome (CACS). Meanwhile, the adverse reactions of chemotherapy and immunotherapy potentially exacerbate the occurrence and…
- Trial name
- NCT07092137
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension
- Volunteers
- 116 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Cachexia-Anorexia Syndrome, Solid Tumor Malignancies
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
This is a clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SXRN Injection in cancer patients with anorexia-cachexia.
- Trial name
- NCT07231120
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients.
- Conditions
- Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
- Trial name
- NCT07633236
- Testing
- OLANZapine 2.5 MG
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Cachexia; Cancer, Cachexia
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH-OLE (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 400 people
- Sponsor
- AVEO Pharmaceuticals, Inc.